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Abstract  
BACKGROUND: Matrix metalloproteinase-9 (MMP9) expression due to ischemic cause spreading of brain 
damage. Previous studies have reported that Bromelin was beneficial as anti-inflammation and prevent brain 
tissue damage.  
AIM: This study aimed to determine the alteration of plasma MMP9 level after addition of Bromelin 500 mg to 
Standard therapy and its correlation with outcome in acute ischemic stroke.  
METHODS: This was a preliminary report of a prospective randomised, double-blind study with pre and post-test 
design, forty-six acute ischemic stroke patients were randomly allocated with Bromelin and Standard groups. 
Measurement of MMP9 and outcome were performed before and after 14-days treatment.  
RESULT: The Bromelin group showed a significant decrement of MMP9 level, from 6.02 ± 0.32 ng/ml before 
treatment to 5.50 ± 0.94 ng/ml after treatment (p = 0.028). There was a negative correlation between MMP9 level 
and mRS (r= -0.03; p = 0.905) and a positive correlation toward BI (r = 0.039; p = 0.859), while the Standard 
group showed increased MMP9 level from 5.82 ± 0.71 ng/ml to 5.91 ± 0.83 ng/ml (p = 0.616) which was 
correlated insignificantly to outcome. 
CONCLUSION: We concluded that the addition of 500 mg Bromelin to standard ischemic stroke therapy reduced 
MMP9 level significantly and correlated to outcome improvement. However, there is a tight statistical correlation. 
 
 
 
 
 
 
Introduction 
 
Ischemic cascade is a complex event and not 
yet understood entirely, but it can be concluded as 
bioenergy failure due to focal brain hypoperfusion 
followed by excitotoxicity, oxidative stress, disruption 
of blood-brain barrier, microvascular injury, hemostatic 
activation, post-ischemic inflammation results in cell 
death, and irreversible dysfunction of neuron cells, 
glial cells, and endothelial cells [1] [2] [3].
 
Up until now, the only FDA (The Food and 
Drug Administration) approved treatment for acute 
ischemic stroke is a thrombolytic therapy using rt-PA 
for reperfusion and save the brain tissue from 
ischemia. This treatment is effective if performed 
within 3 hours after stroke onset (in the USA), or in 
Europe within 4.5 hours. Data from the National 
Institute of Neurological Disorders and Stroke 
(NINDS) rt-PA Stroke Study revealed that rt-PA 
treatment given 3 hours after onset could improve 
clinical outcome and quality of life after 3 months of 
treatment. But until now, the number of patients who 
arrived at the hospital under 3 hour after onset is still 
very low. Also, there are many requirements for this 
therapy can be performed. In the USA, only 10 % of 
the patients receive this facility. In the other hand, 
reperfusion using rt-PA can sometimes cause 
hemorrhagic transformation which can be dangerous 
[4] [5] [6] [7].
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Inflammation is an important aspect of the 
pathophysiology of stroke. Recent studies have 
proved that inflammation and immune response play 
an important role in a person’s vulnerability of having 
stroke and degree of prognosis, this is due to the 
extent of brain tissue damage caused by them. The 
ischemic condition will trigger activation of microglia, 
acting as a sensor and is a resident immune cell in the 
central nervous system. But over activation of 
microglial can be neurotoxic by the release of 
Reactive Oxygen Species (ROS), Nicotinamide 
Dinucleotide Phosphate (NaDPH) oxidase, 
proinflammatory cytokine and induction also activation 
neurovascular proteinase such as matrix 
metalloproteinase (MMP), particularly MMP9. After 
stroke onset, MMP expression becomes uncontrolled, 
as proteolysis that disrupts the integrity of blood-brain 
barrier, causing increased permeability of blood-brain 
barrier leading to brain oedema, neuronal injury, 
apoptosis/cell death. Other than that, the MMP9 
increment will trigger inflammation response through 
resident cells activation and greater leucocyte 
infiltration that can cause oedema to worsen. The 
extent of blood-brain barrier disruption is correlated to 
type, severity and duration of ischemia [2] [5] [8] [9] 
[10] [11] [12] [13] [14] [15] [16] [17]. 
Matrix Metalloproteinase-9 is the most 
common MMP related to stroke event, and many 
interventional studies have been performed with the 
objective to inhibit MMP9 showed better clinical 
outcome. In normal condition, MMP9 expression in 
brain tissue is minimal to undetected [5] [7] [12] [14].
 
Naturally, there is inhibition of MMPs by 
TIMPs. The work of MMPs and their inhibitors are the 
backgrounds of developing a new therapy for acute 
ischemic stroke to suppress the ischemic cascade 
that can spread brain damage so that morbidity and 
mortality from a stroke can be reduced [18].
 
A study by Zhao et al. 2006 (cit. Zlokovic 
2006) on rats reported that rats that had increased 
MMP9 showed worse neurological clinical outcome 
with hemorrhagic complication [18]. The study by 
Yamashita and Abe, 2011 revealed that edaravone 
suppress MMP9 expression which protects brain 
microvascular integrity showed survival improvement 
and neurological clinical outcome [19]. Lo et al. (cit. 
Cui et al. 2012) reported that minocycline, a broad 
spectrum MMP inhibitor can reduce neuronal cell 
death after ischemia and adding time window for 
thrombolytic therapy [14].
 
Bromelin is a proteolytic enzyme (protease) 
fall under hydrolase, which can break peptide bond, 
separating proteins and amino acids. In 2006, FDA 
included Bromelin as a food additive and was a safe 
substance. Its proteolytic activity makes Bromelin 
widely used, for example in the food industry, as a 
supplement, and the substance that prevents 
browning in apple juice, meat tenderiser, an additive 
in the cosmetic industry for peeling effect, leather 
industry for smoothing and washing, and in textile 
industries [22].
 
It is accepted as phytotherapy agent 
and has been accepted as a therapeutic drug for its 
safety and efficacy. It was first introduced in 1957 
(Kelly 1996) for acute inflammation and sports injury. 
This enzyme has broad-spectrum therapeutic efficacy 
proven in vitro and in vivo [20] [21] [23] [24] [25] [26] 
[27].
 
This enzyme has broad-spectrum therapeutic 
efficacy, proved in vitro and in vivo, has anti-oedema 
property, anti-inflammation, antithrombotic, fibrinolytic 
and malignancy. It’s very low toxicity makes this drug 
save to be used in controlling chronic inflammation 
diseases [20] [21] [22] [23] [24] [25] [27] [28] [29] [30].
 
The objective of this study was to determine 
alteration of plasma MMP9 level in acute ischemic 
stroke patients after addition of Bromelin 500 mg 
administered twice a day to standard therapy (aspirin 
300 mg once a day) for 14 days, and its correlation to 
stroke clinical outcome evaluated with modified 
Rankin Scale (mRS) and Barthel Index (BI). 
 
 
Material and Methods 
 
This was a double-blind clinical trial with pre 
and post-test design, performed at Adam Malik 
General Hospital in Medan, Indonesia, within April 
2016 to April 2017, toward acute ischemic stroke 
patients, diagnosed by Head CT-scan. Inclusion 
criteria were acute ischemic stroke patients above 18 
years old, the first attack and giving consent to be 
enrolled in this trial. Exclusion criteria were a 
cardioembolic stroke, brain stem lesion, not having 
upper gastrointestinal bleeding, and not having history 
on using anticoagulant drugs, antiplatelet aggregation 
drugs or anti-inflammation drugs. There were 46 
participants who met the criteria, randomised into 2 
treatment groups: Standard and Bromelin group, with 
23 subjects in each group. All subjects were given 
acetylsalicylic acid (Aptor) 300 mg once a day as 
standard therapy for ischemic stroke. In Bromelin 
group, subjects were given capsule containing 
Bromelin 500 mg by a dose of 2 times daily for 14 
days, while in standard group were given capsule 
containing dextrin 500 mg (Placebo), also twice daily 
for 14 days. Dextrin was chosen as placebo due to not 
having active substance. To meet double-blind 
criteria, Bromelin and placebo were packaged in the 
same colour and weight capsules and administered in 
the same manner also.  
All subjects agreed to participate and signed 
informed consent voluntarily after receiving a detailed 
description of the study procedures and purposes. 
The study was approved by the Health Research 
Ethical Committee of North Sumatera/Adam Malik 
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General Hospital, Medan, c/o Medical School, 
University of Sumatera Utara.  
Blood samples were collected in vacutainer 
tubes. Serum separation was isolated by 
centrifugation at 1000 g over 15 minutes. The serum 
samples should always be pre-diluted 1:5 (100 μl 
serum + 400 μl water) and stored at 2-8
o
C until the 
time of analysis.  
Matrix metalloproteinase-9 concentrations in 
plasma samples were analysed using MMP9 human 
ELISA Assay Kit (EA 100106-Origene) according to 
manufacturers’ instructions and Chemwell 2910 
analyser. Limit of detection of MMP9 human ELISA 
Assay Kit (EA 100106-Origene) is 31 pg/ml or 0.3 
μg/ml.  
The plasma MMP9 level and outcome 
measurement were performed twice, before and after 
treatment. The outcome was determined using 
modified Rankin Scale (mRS) and Barthel Index (BI). 
To evaluate alteration of the MMP9 level before and 
after treatment, paired t-test was used and to 
determine the correlation between plasma MMP9 
level and mRS and BI score, Pearson correlation test 
was used. All data were expressed as mean ± S.D. P 
< 0.05 was considered to be significant. 
 
 
Results 
 
The total subject was 46 participants. 
Bromelin group was consisted of 23 subjects, with 17 
male (73.9 %), while the standard group was also 
comprised of 23 subjects, with 14 male (60.9 %). 
Mean of age in the Bromelin group was 56.04 ± 10.13 
year, while in standard was 60 ± 12.6 year, and there 
was no significant difference between group (p = 
0.583). Subject’s demographic characteristics are 
presented in Table 1. 
Table 1: Demographic Characteristics of Studied Groups 
Characteristics Total Bromelin 500 mg Standard Drug 
N (%) 46 (100%) 23 (50%) 23 (50%) 
Mean Age + SD 58.20 + 11.48 56.04 + 10.13 60 + 12.60 
Gender 
Male (%) 
Female (%) 
 
31 (67.4%) 
15 (32.6%) 
 
17 (73.91%) 
6 (26.09%) 
 
14 (60.87%) 
9(39.13%) 
Marital Status 
Married (%) 
Single (%) 
 
46 (100%) 
0 (0%) 
 
23 (50%) 
0 (0%) 
 
23 (50%) 
0(%) 
Ethnicity 
Bataknese 
Karonese 
Javanese 
Melayunese 
Acehnese 
Padangnese 
 
21 (45.7%) 
5 (10.9%) 
15 (32.6%) 
2 (4.3%) 
1 (2.2%) 
2 (4.3%) 
 
9 (39.13%) 
4 (17.39%) 
8 (34.78%) 
0 (0.00%) 
1 (4.35%) 
1 (4.35%) 
 
12 (52.17%) 
1 (4.35%) 
7 (30.43%) 
2 (8.70%) 
0 (0.00%) 
1 (4.35%) 
Hypertension 
Yes 
No 
 
37 (80.4%) 
9 (19.6%) 
 
18 (78.26%) 
5 (21.74%) 
 
19 (82.61%) 
4 (17.39%) 
Diabetes Mellitus 
Yes 
No 
 
8 (17.4%) 
38 (82.6%) 
 
4 (17.39%) 
19 (82.61%) 
 
4 (17.39%) 
19 (82.61%) 
Hypercholesterolemia 
Yes 
No 
 
37 (80.4%) 
9 (19.6%) 
 
21 (91.30%) 
2 (8.70%) 
 
16 (69.57%) 
7 (30.43%) 
Smoking 
Yes 
No 
 
19 (41.3%) 
27 (58.7%) 
 
10 (43.48%) 
13 (56.52%) 
 
9 (39.13%) 
14 (60.87%) 
N= number of patients; S.D= Standard Deviation. 
 
 There were 23 subjects on the Bromelin 500 
mg group, measured their MMP9 level, mRS score 
and BI score, before and after treatment. Since the 
test of normality showed normal distribution data, 
paired t-test was performed to determine the 
difference of MMP9 level, mRS, and BI score before 
and after treatment, with the level of significance p < 
0.05. 
The result of this study on MMP9 after 
Bromelin 500 mg administration showed significant 
decrement of the MMP9 level. The mean of MMP9 
before treatment was 6.02 ± 0.32 ng/ml and after 
treatment was 5.50 ± 0.4 ng/ml, where the decrement 
was statistically significant (p = 0.028) (Table 2). 
Table 2: Plasma MMP9 Level (ng/ml) and Outcome 
 MMP9 P mRS P BI p 
Drugs Pre Post  Pre Post  Pre Post  
Bromelin 
500mg 
6.02+ 
0.32 
 
5.50+ 
0.94 
0.028* 3+ 
1.107 
2+ 
1.340 
0.604* 50+ 
27.83 
60+ 
30.60 
0.002* 
Standard 
Drugs 
 
5.82+ 
0.71 
5.91+ 
0.83 
0.616* 3+  
0.949 
3+ 
1.033 
0.002* 60+ 
23.45 
75+ 
22.55 
0.001* 
* = Paired T-test 
 
The result of mRS after 500 mg Bromelin 
administration showed unsignificant decrement, where 
mRS score before treatment was 3 ± 1.107 and after 
treatment was 2 ± 1.34 (p = 0.604) (Table 2). 
The study result on BI score after Bromelin 
500 mg administration showed a significant increment, 
where before administration the score was 50 ± 27.83 
and after administration was 60 ± 30.6 with p = 0.002 
(Table 2). 
The result on the MMP9 level in the standard 
group showed unsignificant increment. The mean of 
MMP9 before treatment was 5.82 ± 0.71 ng/ml and 
after treatment was 5.91 ± 0.83 ng/ml, this was not 
statistically significant (p = 0.616) (Table 2). 
This study result on mRS score in standard 
group revealed changes, where before treatment, the 
mRS score was 3 ± 0.949 and after treatment was 3 ± 
1.033 (p = 0.002) (Table 2). 
The result of this study on BI score after 
standard therapy showed significant increment, where 
BI score before treatment was 60 ± 23.45 and after 
treatment was 75 ± 22.55, with p = 0.001 (Table 2). 
Using Pearson correlation test between 
decrement of MMP9 and mRS after Bromelin 500 mg 
administration, there was a negative correlation but 
not statistically significant (r =-0.03; p = 0.905) (Table 
3) 
Table 3: Correlation of MMP9 Decrement and Outcome 
 mRS BI 
 r p r P 
MMP9 
Decrement Level 
 
-0.03 
 
0.905** 
 
0.039 
 
0.859** 
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Pearson correlation test between decrement 
of MMP9 level and increment of BI score showed 
positive unsignificant correlation (r = 0.039; p = 0.859) 
(Table 3) 
 
 
Discussion 
 
Matrix metalloproteinase-9 (MMP9) is a family 
of proteolytic enzyme, involved in the breakdown of 
extracellular matrix during tissue remodelling [7]. The 
action of the MMPs on the basal lamina and tight 
junction proteins (TJPs) in endothelial cells is the final 
common pathway for the opening of the BBB, which 
allows cells to enter the central nervous system and 
attack invading organisms [31]. During a stroke, it 
attacks the extracellular matrix around the blood 
vessels and neurons, facilitating neural cell death.
 
MMP-9 disrupts the blood-brain barrier in the early 
phase following cerebral ischemia, leading to leakage, 
leukocyte infiltration, brain oedema, and haemorrhage 
[7].  
This study found that plasma MMP-9 level to 
be high in the two groups of patients. In Bromelin 
groups mean of the MMP-9 level were 6.02 ± 0.32 
and the Standard group were 5.82 ± 0.71. Expression 
of MMPs in the adult brain is very low to undetectable 
[32]. This study proved that expression of MMP-9 is 
upregulated in the brain in response to ischemic 
stroke. This is by the study by Heo et al. 2003 (cit. 
Abdelnaseera et al. 2015), found that MMP -9 serum 
level on admission was significantly higher in stroke 
patients compared with the control group [33].  
In this study, the addition of Bromelin 500 mg 
to standard therapy showed significant decrement of 
plasma MMP9 level (p 0.028), the increment of mean 
BI score (p = 0.002) and unsignificant decrement of 
mRS score (p = 0.604), proved that clinically there 
was outcome improvement. This concluded that 
MMP9 decrement could improve clinical outcome. 
Study of Lindsell et al. 2005 (cit. Abdelnaseera et al. 
2015) showed there was an association between 
higher serum levels of MMP-9 and more severe 
stroke, supported the role of MMP-9 as an 
independent predictor of clinical severity of ischemic 
stroke in the acute stage [33].
 
Previous several 
studies reported that treatment with MMP inhibitors or 
MMP neutralising antibodies decreases infarct size 
and prevents BBB breakdown after focal ischemic 
stroke [31].  
We concluded that the addition of 500 mg 
Bromelin to standard ischemic stroke therapy reduced 
MMP9 level significantly and correlated to outcome 
improvement. However, there is a tight statistical 
correlation.  
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